NEW YORK (GenomeWeb News) – Quest Diagnostics today pre-announced third quarter earnings results that are expected to fall short of consensus Wall Street estimates.

For the three months ended Sept. 30, the company said that revenues from continuing operations are anticipated to be $1.79 billion, a 2 percent dip from the year-ago period and below analyst expectations of $1.84 billion. Its earnings per share is expected to be $2.66, up from $.98 a year ago. On an adjusted basis EPS is estimated at $1.02, short of Wall Street estimates of $1.20.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Senate committee has unanimously approved a bill to require articles resulting from federally funded projects to be made publicly available, according to ScienceInsider.

The US is heading toward another budget showdown, Nature News says.

In Nature this week: mouse genome functional analysis, more sensitive chromatin immunoprecipitation, and more.

The Center for Data Innovation and HealthITNow argue for re-building of genomic research infrastructure.